Angelo Labate

Full Professor of Neurology

University of Messina
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Angelo Labate is a Full Professor of Neurology at the University of Messina in Italy. His research focuses on various aspects of epilepsy, including clinical features, treatment efficacy, and neuroimaging. Recent articles by Professor Labate explore topics such as the response to uncertainties in epilepsy care, the introduction of new anti-seizure medications, and the genetic underpinnings of familial epilepsy. He actively contributes to the understanding of both common and complex epilepsy conditions through innovative clinical studies and collaborative research.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Objective Epilepsy with generalized tonic–clonic seizures alone (GTCA) is a common but poorly characterized idiopathic generalized epilepsy (IGE) syndrome. Hence, we investigated electroclinical features, seizure outcome, and antiseizure medication (ASM) withdrawal in a large cohort of GTCA patients. Methods In this multicenter retrospective study, GTCA patients defined according to the diagnostic criteria of the International League Against Epilepsy (2022) were included. We investigated prognostic patterns, drug resistance at the last visit, and ASM withdrawal, along with their prognostic factors. Results We included 247 patients with a median (interquartile range [IQR]) age at onset of 17 years (13–22) and a median follow‐up duration of 10 years (IQR = 5–20). Drug resistance at the last visit was observed in 40 (16.3%) patients, whereas the median latency to achieve 2‐year remission was 24 months (IQR = 24–46.5) with a median number of 1 (IQR = 1–2) ASM. During the long‐term follow‐up (i.e., 202 patients followed ≥5‐years after the first ASM trial), 69 (34.3%) patients displayed an early remission pattern and 36 (17.9%) patients displayed a late remission pattern, whereas 16 (8%) and 73 (36.3%) individuals had no‐remission and relapsing–remitting patterns, respectively. Catamenial seizures and morning predominance of generalized tonic–clonic seizures (GTCS) independently predicted drug resistance at the last visit according to multivariable logistic regression. Treatment withdrawal was attempted in 63 (25.5%) patients, with 59 (93.7%) of them having at least a 12‐month follow‐up after ASM discontinuation. At the last visit, 49 (83%) of those patients had experienced GTCS recurrence. A longer duration of seizure freedom was the only factor predicting a higher chance of successful ASM withdrawal according to multivariable Cox regression. Significance GTCA could be considered a relatively easily manageable IGE syndrome, with a low rate of drug resistance and a high prevalence of early response to treatment. Nevertheless, a considerable proportion of patients experience relapsing patterns of seizure control, highlighting the need for appropriate counseling and lifestyle recommendations.

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (16)

Christoph P. Beier

-

DENMARK
View details

Elena Merli

IRCCS Istituto Delle Scienze Neurologiche di Bologna

ITALY
View details

Christian Rummel

-

SWITZERLAND
View details

Antonio Gambardella

Professor of Neurology

Università degli Studi Mediterranea di Reggio Calabria

ITALY
View details

Andre Altmann

University College London

UNITED KINGDOM
View details

Elisa Bianchi

Mario Negri Institute for pharmacological research

ITALY
View details

Magdalena Kowalczyk

University of Melbourne

AUSTRALIA
View details

Eugenio Abela

Head

Psychiatrische Dienste Aargau AG

SWITZERLAND
View details

Enrico Iaccino

-

ITALY
View details

Rebekah V Harris

University of Melbourne

AUSTRALIA
View details

Maria Eugenia Caligiuri

-

ITALY
View details

Ilaria Sammarra

Magna Graecia University

ITALY
View details

Gloria Bertoli

Istituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche

ITALY
View details

Ingrid Scheffer

University of Melbourne

AUSTRALIA
View details

Piero Perucca

-

AUSTRALIA
View details

Saul Mullen

University of Melbourne

AUSTRALIA
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.